Literature DB >> 33758623

YTHDF1 gene polymorphisms and neuroblastoma susceptibility in Chinese children: an eight-center case-control study.

Jiabin Liu1, Jiwen Cheng2, Li Li3, Yong Li4, Haixia Zhou5, Jiao Zhang6, Suhong Li7, Huimin Xia1, Jing He1, Zhonghua Yang8.   

Abstract

Neuroblastoma is one of the most common life-threatening extracranial tumors that mainly occurs in children, and its genetic etiology remains largely obscure. RNA m6A modification has been thought to play a key role in cancer progression. YTHDF1 is the critical downstream gene by which RNA m6A modification exerts its functions. Single nucleotide polymorphisms in the YTHDF1 gene may affect its expression and biological activity, thereby leading to abnormalities in the regulation of downstream m6A-modified RNA and eventually promoting the initiation and development of tumors. Here, we attempted to evaluate the contributions of two polymorphisms (rs6011668 C>T and rs6090311 A>G) in the YTHDF1 gene to neuroblastoma susceptibility in 898 cases and 1734 controls that originated in China. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in the logistic regression models to evaluate the associations between selected polymorphisms and neuroblastoma risk. Overall, either in a single locus or combination analysis, no significant association with neuroblastoma risk was found for either of the two selected polymorphisms. However, the stratified analysis showed that rs6090311AG/GG genotypes significantly reduced the neuroblastoma risk in males (adjusted OR=0.77, 95% CI=0.62-0.96, P=0.018). Moreover, we found that subjects with 2 protective genotypes had a lower tumor risk in males than in those with 0-1 protective genotypes (adjusted OR=0.77, 95% CI=0.62-0.96, P=0.018). In summary, our study indicates that YTHDF1 gene polymorphisms may weakly contribute to neuroblastoma susceptibility. Our findings should be further verified by well-designed studies with larger sample sizes. © The author(s).

Entities:  

Keywords:  YTHDF1; m6A modification.; neuroblastoma susceptibility; polymorphism

Year:  2021        PMID: 33758623      PMCID: PMC7974895          DOI: 10.7150/jca.54496

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  4 in total

1.  YTHDF2 Gene rs3738067 A>G Polymorphism Decreases Neuroblastoma Risk in Chinese Children: Evidence From an Eight-Center Case-Control Study.

Authors:  Huijuan Zeng; Meng Li; Jiabin Liu; Jinhong Zhu; Jiwen Cheng; Yong Li; Jiao Zhang; Zhonghua Yang; Li Li; Haixia Zhou; Suhong Li; Huimin Xia; Yan Zou; Jing He; Tianyou Yang
Journal:  Front Med (Lausanne)       Date:  2021-12-14

2.  Identification and Characterization of a Glucometabolic Prognostic Gene Signature in Neuroblastoma based on N6-methyladenosine Eraser ALKBH5.

Authors:  Kezhe Tan; Wei Wu; Kai Zhu; Li Lu; Zhibao Lv
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

3.  Association of N6-methyladenosine readers' genes variation and expression level with pulmonary tuberculosis.

Authors:  Hong-Miao Li; Fei Tang; Li-Jun Wang; Qian Huang; Hai-Feng Pan; Tian-Ping Zhang
Journal:  Front Public Health       Date:  2022-08-22

4.  Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.

Authors:  Chundi Gao; Huayao Li; Wenzhe Ma; Qiming Zhang; Cun Liu; Lijuan Liu; Jing Zhuang; Changgang Sun
Journal:  J Immunol Res       Date:  2022-08-23       Impact factor: 4.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.